As of 25th May 2018, the European General Data Protection Regulation (GDPR) became applicable in all member states. There has been a lot of hype, fear and angst about what this new
regulation means for real-world research. While the regulation provides some risk to companies, the regulation also provides opportunities specific to scientific research. Stuart McCully at
Syneos Health explains that GDPR doesn’t stop life sciences companies from doing scientific research or accessing and using patient data, instead it ensures that data protection is at the
forefront of everyone’s minds from the very beginning of the clinical development process.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/10/GDPR-and-the-implications-on-real-world-research.pdf” width=”100%” height=”900px” style=”border:0;”]